论文部分内容阅读
目的探讨替加环素联合美罗培南治疗新生儿重症多重耐药菌感染的临床效果及安全性。方法选取2014年1月至2016年12月广东省佛山市第一人民医院收治的10例重症多重耐药菌感染新生儿作为研究对象,对其予以替加环素与美罗培南联合治疗。观察患儿的临床治疗效果及治疗前后白细胞计数(WBC)、C反应蛋白(CRP)、血清降钙素原(PCT)、中性粒细胞(N)、氧合指数(Pa O2/Fi O2)以及不良反应发生情况。结果本组患儿中,治愈5例,显效3例,有效1例,无效1例,治疗的总有效率为90.0%(9/10);治疗后患儿的WBC、CRP、PCT、N均明显低于治疗前,而Pa O2/Fi O2显著高于治疗前,差异均有统计学意义(均P<0.05);10例患儿中,出现皮疹1例,不良反应发生率为10.0%。结论对重症多重耐药菌感染患儿予以替加环素与美罗培南联合治疗,效果显著,且不良反应少,安全性高。
Objective To investigate the clinical efficacy and safety of tigecycline combined with meropenem in the treatment of severe multi-drug resistant infections in newborns. Methods From January 2014 to December 2016, 10 newborns with severe multi-drug-resistant bacterial infections admitted to the First People’s Hospital of Foshan City, Guangdong Province were selected as the study subjects and treated with combination of tigecycline and meropenem. The clinical efficacy and the changes of WBC, C-reactive protein (CRP), serum procalcitonin (PCT), neutrophil (N), oxygenation index (Pa O2 / Fi O2) As well as the occurrence of adverse reactions. Results In this group of children, 5 cases were cured, 3 cases markedly effective, 1 effective and 1 ineffective, and the total effective rate was 90.0% (9/10). The WBC, CRP, PCT, N (P <0.05). In 10 cases, there was 1 case of rash and the incidence of adverse reactions was 10.0%. Conclusions The combined treatment of tigecycline and meropenem in children with severe multi-drug-resistant bacterial infection has significant effect with less adverse reactions and high safety.